Tacton Launches Portfolio Performance Intelligence to Help Manufacturers Understand Why Products Win
30.6.2026 15:00:00 CEST | Business Wire | Press release
New configuration-aware commercial intelligence capability connects customer requirements, configuration decisions, and business outcomes to optimize win rates, margin and product strategy.
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of Portfolio Performance Intelligence, a new analytics capability designed to help manufacturers understand why products win, where margin is created or lost, and which decisions consistently drive successful business outcomes.
Manufacturers don't lack data. They lack the context needed to understand why products perform the way they do and why customers choose them.
ERP systems show what was sold, CRM platforms track opportunities, and BI tools visualize trends. But when manufacturers try to understand which customer requirements drive demand, which configurations consistently win, or why margins vary across products, regions or segments, the answers are often unclear.
That's because the most important layer of insight–the connection between customer needs, configuration decisions and deal outcomes–only exists within CPQ.
“As product complexity increases and margin pressure continues to grow, manufacturers need more than just historical reporting,” said Jesper Alfreddson, Chief Product Officer at Tacton. “Portfolio Performance Intelligence extends Tacton CPQ with configuration-aware commercial intelligence, helping teams get direct visibility into how product, pricing, and configuration decisions impact business outcomes, so they can act faster and more confidently.”
Built directly into Tacton CPQ, Portfolio Performance Intelligence connects customer requirements, configuration decisions, pricing, and business outcomes to help manufacturers understand what drives revenue, margin, and portfolio performance. By revealing which configurations, features, and pricing decisions consistently lead to successful outcomes, manufacturers can replicate what works across products, regions, and customer segments.
With Portfolio Performance Intelligence, product, sales, and commercial teams can:
- Identify the configuration patterns that consistently drive wins
- Understand which products, features and combinations protect margin
- Reduce unnecessary portfolio complexity and low-performing variants
- Improve sales velocity by identifying where deals slow down or stall
- Improve future pricing, portfolio forecasting and go-to-market decisions
Unlike traditional analytics environments that require manual data preparation and recreation of complex product logic, Portfolio Performance Intelligence is purpose-built for configurable manufacturing and embedded directly within Tacton CPQ, where customer requirements become product, pricing, and configuration decisions.
As manufacturers face increasing pressure to manage complexity, improve efficiency and protect profitability, the ability to connect decisions to outcomes is critical.
Portfolio Performance Intelligence is the latest capability within Tacton Insights & Analytics, Tacton's embedded analytics platform designed to help manufacturers unlock the full value of CPQ data. The platform also includes Behavior & Engagement Analytics, providing visibility into CPQ adoption and usage.
Portfolio Performance Intelligence will be available in July 2026. Learn more here.
About Tacton
Tacton is a global leader in software for manufacturers of highly configurable products. Tacton delivers the Buyer-Centric Smart Factory, connecting buyer engagement with engineering and order fulfillment through a single source of truth.
By uniting Configure Price and Quote, Configuration Lifecycle Management, and Configured Order Fulfillment, Tacton helps manufacturers manage complexity, protect margins, and deliver with confidence across the lifecycle.
With more than 26 years of experience, Tacton supports manufacturers worldwide and is headquartered in Stockholm, Sweden and Chicago, USA. Learn more at www.tacton.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260630278615/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 15:00:00 CEST | Press release
New end-to-end resilience and managed security offerings help organizations reduce security complexity, cut system downtime by up to 50%, and lower remediation costs by up to 40% by bringing devices, security technologies, expert services, and ecosystem partners together under a single operational model As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations
SC Therapeutics Initiates REACH2 Trial for Refractory Chronic Cough30.6.2026 15:00:00 CEST | Press release
First-in-class disease-modifying therapeutic aerosol targeting mechano-sensitive ion channels advances into phase 2 clinical evaluation in UK SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports initiation of the REACH2 trial. The study will evaluate the Company's lead product candidate in patients with refractory chronic cough (RCC) – a debilitating condition for which no disease-modifying treatment options currently exist. The trial will be run in three major cough centers across the UK. A Novel, Disease-Modifying Mechanism of Action SC0032, SC Therapeutics' most advanced product candidate, is a proprietary therapeutic aerosol composed entirely of ions endogenous to human airways. Unlike current symptomatic investigational drugs – including P2X3 receptor antagonists and neurokinin-1 (NK1) receptor antagonists that seek to dampen neural hyper
Riskified Study: As AI Drives a Summer Travel Boom, Clunky Security and Scam Fears Threaten Merchant Conversions30.6.2026 14:30:00 CEST | Press release
New 2026 Summer Travel Survey from Riskified finds that digital and AI tools are reshaping how trips are planned, while security and authenticity concerns continue to influence checkout decisions Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released findings from global survey conducted ahead of the 2026 Summer Travel season, exploring consumer travel behavior, booking experiences, and trust in digital and AI-enabled travel tools. The survey, conducted among more than 4,000 consumers across the United States, United Kingdom, China, Japan, Mexico, Brazil, and Colombia, shows strong demand for travel heading into the summer season, alongside continued adoption of digital and AI tools in trip planning. Key findings from the Riskified 2026 Summer Travel Survey include: 81% of consumers use digital platforms for travel planning, with 26% already relying on AI like ChatGPT or Gemini. Leisure remains the dominant purpose of travel at 63%, followed by
Corpay Cross-Border Named the Official Global FX Partner of Fever30.6.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, today announced that its Cross-Border business has entered into an agreement with Fever, a leading global live-entertainment discovery and ticketing platform that specializes in immersive experiences, candlelit concerts, and interactive pop-up events. Under the agreement, Corpay becomes Fever’s exclusive and Official Global Foreign Exchange (FX) Partner. Through this partnership, Fever’s global operations across North America, Mexico, the UK, EMEA, and APAC will be able to leverage Corpay Cross-Border’s innovative solutions to help manage foreign exchange exposure arising from day-to-day business activities. “Fever represents the future of global live entertainment and event ticketing technology, and we are honoured to be named their exclusive and Official FX Partner,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions.
Allegro DVT Plays a Pivotal Role in Groundbreaking CHASSIS Automotive Base Die Development30.6.2026 14:15:00 CEST | Press release
Allegro DVT announced its contribution to the European CHASSIS program's implementation of the Automotive Base Die chiplet. The 5nm chiplet is set to revolutionize the automotive semiconductor landscape, laying the foundation for the open and standardized chiplet ecosystem that will enable the next generation of software-defined vehicles. The Automotive Base Die acts as the central communication and integration hub for automotive System-on-Chip (SoC) infrastructure, which is designed to enable seamless integration of third-party chiplets via the Universal Chiplet Interconnect Express (UCIe) standard. The Automotive Base Die is funded within the Chips JU program CHASSIS by leading European entities BMW, imec, and Bosch, which aims to enable unprecedented flexibility and innovation in the automotive industry. Allegro DVT’s expertise has been instrumental in the development of this foundational technology. Specifically, Allegro DVT has provided its Encoding and Decoding Semiconductor Vide
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom